Abatacept now available on NHS for rheumatoid arthritis

NICE has overturned its original decision to reject the rheumatoid arthritis treatment abatacept (Orencia).

Abatacept inhibits the activation of T cells, a key step in the development of rheumatoid arthritis.
Abatacept inhibits the activation of T cells, a key step in the development of rheumatoid arthritis.

In a review of its 2008 guidance, the institute has ruled that abatacept, in combination with methotrexate, can be considered for adults with severe active rheumatoid arthritis who are unresponsive or intolerant to a DMARD (including at least one TNF inhibitor) and in whom rituximab is unsuitable.

Adalimumab, etanercept and infliximab are recommended as other treatment options alongside abatacept.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

'Life-changing' migraine drug approved by NICE

'Life-changing' migraine drug approved by NICE

The decision by NICE means patients with chronic migraine...

Quadruple therapy should be 'new therapeutic standard' for heart failure, say researchers

Quadruple therapy should be 'new therapeutic standard' for heart failure, say researchers

Treatment with a four-drug regimen incorporating newer...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...